What is a stock summary page? Click here for an overview.
Business Description
Vivos Therapeutics Inc
NAICS : 325413
SIC : 5047
ISIN : US92859E2072
Share Class Description:
VVOS: Ordinary SharesDescription
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.84 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -9.16 | |||||
| Beneish M-Score | -1.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -23.6 | |||||
| 3-Year EBITDA Growth Rate | 14.4 | |||||
| 3-Year EPS without NRI Growth Rate | 20.7 | |||||
| 3-Year FCF Growth Rate | 2.4 | |||||
| 3-Year Book Growth Rate | -78.7 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.45 | |||||
| 9-Day RSI | 55.42 | |||||
| 14-Day RSI | 50.75 | |||||
| 3-1 Month Momentum % | -37.35 | |||||
| 6-1 Month Momentum % | 1.3 | |||||
| 12-1 Month Momentum % | -36.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.44 | |||||
| Quick Ratio | 1.44 | |||||
| Cash Ratio | 1.23 | |||||
| Days Sales Outstanding | 9.03 | |||||
| Days Payable | 121.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -36.1 | |||||
| Shareholder Yield % | 2.06 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.8 | |||||
| Operating Margin % | -85.72 | |||||
| Net Margin % | -86.19 | |||||
| FCF Margin % | -89.62 | |||||
| ROE % | -417.51 | |||||
| ROA % | -98.13 | |||||
| ROIC % | -114.06 | |||||
| 3-Year ROIIC % | -369.65 | |||||
| ROC (Joel Greenblatt) % | -271.67 | |||||
| ROCE % | -210.1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.65 | |||||
| PB Ratio | 2.24 | |||||
| Price-to-Tangible-Book | 3.88 | |||||
| EV-to-EBIT | -1.28 | |||||
| EV-to-EBITDA | -1.34 | |||||
| EV-to-Forward-EBITDA | -3.72 | |||||
| EV-to-Revenue | 1.1 | |||||
| EV-to-Forward-Revenue | 0.81 | |||||
| EV-to-FCF | -1.22 | |||||
| Price-to-GF-Value | 2.56 | |||||
| Earnings Yield (Greenblatt) % | -78.13 | |||||
| FCF Yield % | -61.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VVOS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vivos Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14.581 | ||
| EPS (TTM) ($) | -5.68 | ||
| Beta | 9.07 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 1.43 | ||
| Volatility % | 76.34 | ||
| 14-Day RSI | 50.75 | ||
| 14-Day ATR ($) | 0.311325 | ||
| 20-Day SMA ($) | 3.431 | ||
| 12-1 Month Momentum % | -36.46 | ||
| 52-Week Range ($) | 1.91 - 6.28 | ||
| Shares Outstanding (Mil) | 5.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vivos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vivos Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vivos Therapeutics Inc Frequently Asked Questions
What is Vivos Therapeutics Inc(VVOS)'s stock price today?
The current price of VVOS is $3.61. The 52 week high of VVOS is $6.28 and 52 week low is $1.91.
When is next earnings date of Vivos Therapeutics Inc(VVOS)?
The next earnings date of Vivos Therapeutics Inc(VVOS) is 2025-03-28 Est..
Does Vivos Therapeutics Inc(VVOS) pay dividends? If so, how much?
Vivos Therapeutics Inc(VVOS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers